Cyclosporine.
Cyclosporine is an immunosuppressant used to prevent the rejection of transplanted kidneys, hearts, and livers. Cyclosporine suppresses T-lymphocyte function without causing myelosuppression, and its pharmacokinetics are highly variable. Compared with conventional immunosuppressive drug therapy, both patient and graft survival improved in patients treated with cyclosporine. Patients treated with cyclosporine also had less complicated hospital courses than patients receiving conventional immunosuppressants. The adverse effects from cyclosporine are reversible but include nephrotoxicity, hepatotoxicity, malignancies, hirsutism, and minor neurologic complications. Intravenous cyclosporine doses range from 2-9 mg/kg/d and oral doses range from 10-50 mg/kg/d; the dosage should be individualized based on the clinical status of the patient as well as blood concentrations of the drug. Monitoring cyclosporine blood concentrations is necessary in the postoperative management of transplant patients. Cyclosporine has contributed to the improved success of transplantation and the recognition of transplantation as a new therapeutic option for several diseases.
D000818:Animals; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D003524:Cyclosporins / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004285:Dogs; D004347:Drug Interactions; D006086:Graft vs Host Disease / Q000517:prevention & control; D016027:Heart Transplantation; D006801:Humans; D007408:Intestinal Absorption; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation; D007700:Kinetics; D016031:Liver Transplantation; D014018:Tissue Distribution
D003524:Cyclosporins